AU2020218639A1 - Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein - Google Patents

Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein Download PDF

Info

Publication number
AU2020218639A1
AU2020218639A1 AU2020218639A AU2020218639A AU2020218639A1 AU 2020218639 A1 AU2020218639 A1 AU 2020218639A1 AU 2020218639 A AU2020218639 A AU 2020218639A AU 2020218639 A AU2020218639 A AU 2020218639A AU 2020218639 A1 AU2020218639 A1 AU 2020218639A1
Authority
AU
Australia
Prior art keywords
hydroxyvitamin
patient
serum
treatment
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020218639A
Other languages
English (en)
Inventor
Charles W. Bishop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eirgen Pharma Ltd
Original Assignee
Eirgen Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirgen Pharma Ltd filed Critical Eirgen Pharma Ltd
Publication of AU2020218639A1 publication Critical patent/AU2020218639A1/en
Priority to AU2025259887A priority Critical patent/AU2025259887A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AU2020218639A 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein Abandoned AU2020218639A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025259887A AU2025259887A1 (en) 2019-02-06 2025-10-30 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802148P 2019-02-06 2019-02-06
US62/802,148 2019-02-06
PCT/IB2020/000089 WO2020161543A1 (en) 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025259887A Division AU2025259887A1 (en) 2019-02-06 2025-10-30 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Publications (1)

Publication Number Publication Date
AU2020218639A1 true AU2020218639A1 (en) 2021-08-12

Family

ID=69903711

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020218639A Abandoned AU2020218639A1 (en) 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
AU2025259887A Pending AU2025259887A1 (en) 2019-02-06 2025-10-30 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025259887A Pending AU2025259887A1 (en) 2019-02-06 2025-10-30 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Country Status (9)

Country Link
US (1) US20220226351A1 (https=)
EP (1) EP3920938A1 (https=)
JP (2) JP2022519789A (https=)
KR (1) KR20210126023A (https=)
CN (1) CN113573714A (https=)
AU (2) AU2020218639A1 (https=)
CA (1) CA3128153A1 (https=)
MX (1) MX2020011741A (https=)
WO (1) WO2020161543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593047T3 (es) * 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US11752158B2 (en) * 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
AU2013203489B2 (en) * 2008-07-24 2015-02-05 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
WO2011123476A1 (en) * 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
AU2019248829B2 (en) * 2018-04-03 2025-02-06 Opko Ireland Global Holdings, Ltd. Use of calcifediol in bariatric surgery patients

Also Published As

Publication number Publication date
KR20210126023A (ko) 2021-10-19
JP2025031720A (ja) 2025-03-07
MX2020011741A (es) 2021-03-02
US20220226351A1 (en) 2022-07-21
JP2022519789A (ja) 2022-03-24
AU2025259887A1 (en) 2025-11-20
EP3920938A1 (en) 2021-12-15
WO2020161543A1 (en) 2020-08-13
CN113573714A (zh) 2021-10-29
CA3128153A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
AU2020267276B2 (en) Adjunctive therapy with 25-hydroxyvitamin d
AU2023200536B2 (en) Methods of vitamin D treatment
AU2025259887A1 (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
Bishop et al. Extended-release calcifediol normalized 1, 25-dihydroxyvitamin D and prevented progression of secondary hyperparathyroidism in hemodialysis patients in a pilot randomized clinical trial
US11590148B2 (en) Use of calcifediol in bariatric surgery patients
HK40063649A (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
WO2025094144A1 (en) Controlling loss of kidney function
HK40130461A (en) Methods of vitamin d treatment
Matsushita et al. Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients
BR122024014371A2 (pt) Usos de 25-hidroxivitamina d e de calcifediol para tratar hiperparatiroidismo secundário e forma de dosagem de liberação prolongada de 25-hidroxivitamina d

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted